A 10-minute subcutaneous formulation of Roche’s multiple sclerosis (MS) blockbuster Ocrevus (ocrelizumab) could be a convenient alternative to a two-hour intravenous infusion and could expand access for patients for whom it is difficult to reach an infusion center. The US Food and Drug Administration approved Ocrevus Zunovo (ocrelizumab and hyaluronidase) on 13 September.
Key Takeaways
-
The US FDA approved a new subcutaneously administered version of Roche’s blockbuster multiple sclerosis drug Ocrevus.
-
A subcutaneous formula could be more convenient for some patients over the original two-hour intravenous infusion
The two formulations will be priced the same, though a subcutaneous administration can avoid some administration costs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
